Checkmate Capital Group

Bredis is a technology company specializing in medical device technology commercialization, research, and development. It focuses on digital health tools for early diagnosis and personalized management of brain disorders, offering biomarker detection and cognitive training features to enhance healthcare provider and patient outcomes.

Lynx Biosciences, Inc. is a clinical-stage biotechnology company based in La Jolla, California, founded in 2013. The company focuses on developing innovative solutions for blood cancer therapies by utilizing a cytomics-based platform technology. Its flagship product, MicroC3, leverages patient biopsy samples to create personalized cancer models that help determine individual responses to various treatments. By integrating physiologically relevant suspension cell co-culture assays, automated microfluidics, and advanced deep learning analytics, Lynx Biosciences aims to enhance the precision of patient management and expedite the advancement of promising drug candidates in oncology. The company's mission is to deliver tailored cancer treatments that significantly improve outcomes for blood cancer patients, including those with multiple myeloma.

MAIA Biotechnology is a biopharmaceutical company focused on developing targeted immunotherapies for cancer. Its lead asset, THIO, is an investigational drug candidate that targets telomeres and enhances immune response.

Elucid is a Boston-based biotechnology and medical technology company dedicated to enhancing cardiovascular diagnostic imaging through machine learning. The company has developed ElucidVivo, the first FDA-cleared software that evaluates plaque vulnerability from a single computed tomography angiography scan, aiding in the assessment of heart attack and stroke risks as well as informing treatment decisions. Elucid's technology enables objective quantification of arterial plaque extent and stability, providing a cost-effective and non-invasive means of capturing essential patient health information. In addition to its proprietary software, Elucid collaborates with pharmaceutical companies, healthcare providers, and research organizations to offer quantitative image analysis services, ultimately aiming to improve patient outcomes in cardiovascular care.

Lactiga is a biotherapeutics company focused on developing innovative biologics aimed at treating and preventing infections, particularly for patients with Primary Immunodeficiency Diseases. By harnessing the therapeutic potential of human milk, Lactiga seeks to combat severe pathogens and improve the quality of life for individuals with rare immunodeficiencies, such as selective IgA deficiency and common variable immunodeficiency. The company's biotherapeutics are designed to prevent mucosal infections, enabling immunodeficient and immunocompromised individuals to lead healthier lives without the need for invasive treatments.

Founded in 2011, Monarch Biosciences is a biotechnology company based in Los Angeles, California. It specializes in the development of medical devices and biotechnology products using thin film nitinol technology for local delivery of cell therapies to treat solid tumors.

Bcause, LLC is a Virginia Beach-based company that provides a trading platform for options contracts denominated in various digital currencies and traditional fiat currencies. Founded in 2013, Bcause focuses on offering solutions for the expanding digital currency market, aiming to reduce the risks associated with holding cryptocurrencies like bitcoin. The platform enables users to engage in regulated trading of futures and options, facilitating both limit and market orders. By catering to the needs of traders in the digital currency ecosystem, Bcause seeks to enhance the overall trading experience while addressing the unique challenges posed by this emerging financial landscape.

SiteFuel, Inc. operates a digital fuel management and exchange marketplace that connects fuel suppliers and independent haulers with businesses and government agencies in need of fuel. Founded in 2015 and based in Newport Beach, California, the company facilitates the buying and selling of fuel by providing real-time information and invoices based on market pricing at the time of delivery. SiteFuel is designed to streamline the fuel procurement process, ensuring timely and efficient deliveries to various job sites nationwide, even in challenging locations. The platform's technology allows customers to maintain operations without interruption, effectively managing their fuel needs with the support of multiple suppliers.

TELA Bio is a medical technology company specializing in soft tissue reconstruction. It designs, develops, and markets the OviTex Reinforced Tissue Matrix portfolio for hernia repair and abdominal wall reconstruction, as well as OviTex PR Reinforced Tissue Matrix for plastic and reconstructive surgery and OviTex for laparoscopic and robotic procedures. The reinforced matrices are derived from ovine rumen with polypropylene fiber and are intended to address unmet needs in soft tissue repair while emphasizing preservation of anatomy and minimizing long-term exposure to permanent synthetic materials. The company markets its products through a single direct sales force, principally in the United States. Founded in 2012 and headquartered in Malvern, Pennsylvania.